Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06448039 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

In-office Repair of Chronic Tympanic Membrane Perforations

StatusActive, Not Recruiting
PhasePhase 1/2
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Trial status: Suspended to Active, Not Recruiting
    • Primary completion date changed from estimate of Aug 30, 2026 to May 13, 2026
    v4
  2. Trial status: Not Yet Recruiting to Suspended Sponsor's reason: Study drug is no longer available from Nobelpharma
    • Primary completion date: Sep 30, 2025 to Aug 30, 2026
    • Study completion date: Dec 30, 2025 to Dec 30, 2026
    • Eligibility criteria shortened, about 11 words
    v3
  3. Primary endpoints: 1 to 2
    • Study description expanded, about 4 words
    v2
  4. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The goal of this clinical trial is to compare the application of fibroblast growth factor 2 (FGF2) with normal saline for the healing of chronic tympanic membrane (TM) perforations. This is an extension of a prior study. The main question it aims to answer is: Will modifications to our prior surgical trial provide higher success rates in obtaining complete closure of chronic tympanic membrane perforations? Twenty participants will be randomized in a controlled study to FGF2 or saline in a 3:1 ratio and the total tympanic membrane closure compared.
Trial Details
NCT Number NCT06448039
Lead Sponsor D. Bradley Welling, MD, PhD
Collaborators: Nobelpharma
Conditions
(from sponsor)		 Chronic Tympanic Membrane Perforation
Enrollment 20 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov